What good is data if it’s not transformed into insights that compel policy makers to take action? Happy to be invited by @NASTAD to present #HCV Data for Action, sharing the impact of modeling and means to influence policy makers at #CSTE2019 alongside @AnnetteGaudino. @CDAFound
Congratulated @Homie_Razavi & @RickJDunn@CDAFound on completing 🇺🇿Hepatitis Elim Program w/ the most affordable & adv treatment. 62K patients screened & $1,2 mln invested. Wish you all the success w/ a new @CDCgov supported project on digitalizing the medical database in 6 regs.
Please join us in congratulating @LewisRobertsMD who has been named the first Associate Chair for Equity, Inclusion, and Diversity for the @MayoClinic Division of Gastroenterology and Hepatology.
The world has lost a great man, scientist and philanthropist. He will be dearly missed. My condolences to the family and specially the very dear Dr. Lily Lou.
@Homie_Razavi In related news, people living with #hepatitis have launched urgent campaign to end meetings by 2025. Targets include 80% of participants excluded from future meetings, 90% reduction of recurring meetings and 85% reduction in new meetings. #endmeetings2025 😖 #nozoom
Professor Erkin Musabaev, our co-investigator in Uzbekistan, won the Presidential Medal of Honor last month. We are proud of working together on the #UHEP project.
@CDAFound@RickJDunn@Hep_Alliance#HCV#HBV
The Discovery of #Hepatitis C—The 2020 @NobelPrize in Physiology or Medicine.
"The prize recognizes not just the contribution of these three outstanding scientists, but also the critical importance
of hepatitis C in world health."→https://t.co/6N3jrCsx7l via @NEJM#HCV#HepC
#COVID19 is slowing down the progress in #HepC elimination. This study estimates that 1 yr delay from COVID19 in #HCV elimination may result in 78K excess deaths and worsen socioeconomic disparities. Free at https://t.co/Y4cv0JsunM @SarahJBlach@CDAFound@Homie_Razavi@EASLnews
Is #HCV elimination cost effective? The answer is yes, if the program is set up properly.
The cost‐effectiveness of hepatitis C virus elimination in low‐ and middle‐income countries https://t.co/YgyTJFeKAA
~200 experts have endorsed the case for simplifying and using absolute targets for viral hepatitis elimination goals.
A big thanks to everyone who collaborated on this paper.
Where do you stand on this topic?
#nohep@CDAFound@Hep_Alliance
https://t.co/KzomJUp7fH
#COVID19 is slowing down the progress in #HepC elimination. This study estimates that 1 yr delay from COVID19 in #HCV elimination may result in 78,000 excess deaths and worsen socioeconomic disparities. Free at https://t.co/Y4cv0JK5Mm @SarahJBlach@CDAFound@Homie_Razavi#NoHep
🚨A must-read @NatRevGastroHep Review on #epidemiology of acute & chronic viral #hepatitis infection in #pregnancy, effect of pregnancy on the course of viral infection & influence of the viral infection on maternal & infant outcomes, including #MTCT→https://t.co/m68BB0vR2p
The unsung heroes of the Nobel-winning #hepatitis C discovery. A tight-knit team of scientists worked feverishly to identify the deadly virus. Only one of them was awarded the #NobelPrize→https://t.co/jh7PBhjGHO via @heidiledford @NatureNews @nresearchnews #HCV#HepC#HepatitisC
French #hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long→https://t.co/dsHjGeV7tW @santeprevention🇫🇷@BioMedCentral#HCV#HepC#HepatitisC